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Hematopoietic cell transplant (HCT) has been successfully used to treat a large number of patients 
with a variety of hematological disorders. Use of unrelated donor cells has greatly expanded the 
number of patients treated by HCT, however these patients are at a higher risk for post-transplant 
complications resulting from genetic disparities between donor and patient. To minimize the risk of 
acute graft-versus-host disease (aGVHD) and mortality following HCT, unrelated patients and 
donors are matched for ten alleles of HLA-A, C, B, DRB1 and DQB1, genes of the human leukocyte 
antigen (HLA) system. Mismatches at an additional HLA allele, HLA-DPB1, increase the risk of 
aGVHD, however HLA-DPB1 matched donors are very difficult to find and hence, this gene is not 
routinely considered for donor selection. Furthermore, HLA-DPB1 mismatches associate with a 
lower risk of relapse. To better understand how HLA-DPB1 mismatches influence patient outcome, 
Dr. Effie Petersdorf and colleagues in the Clinical Research Division and the International 
Histocompatibility Working Group (IHWG)*, used a novel concept of mapping T-cell epitopes to 
classify HLA-DPB1 mismatches associated with increased risk (“non-permissive”) and mismatches 
that did not negatively impact clinical outcome (“permissive”). 
As Project Leader of the Transplantation Working Group and host to the IHWG, Dr. Petersdorf et 
al. were able to examine the effect of HLA-DPB1 T-cell epitope mismatches on aGVHD in more than 
8500 unrelated donor transplants, of which 5428 were matched for all ten HLA alleles and 3111 
were matched for 9 of 10 HLA alleles. Of the group overall, 20% were HLA-DPB1 matched, 49% 
were permissive HLA-DPB1 mismatches, and 31% were non-permissive HLA-DPB1 mismatches. 
Outcomes for patients transplanted from donors with HLA-DPB1 permissive misma`tches were 
similar to those of patients transplanted from HLA-DPB1 matched donors. In contrast, in both the 
9/10 and 10/10 HLA-allele matched populations, HLA-DPB1 non-permissive mismatches were 
associated with a significantly increased risk of severe aGVHD, overall mortality, and non-relapse 
mortality. 
 In conclusion, these data provide a better understanding of HLA-DPB1 mismatches on patient 
outcome and will aid in more precise risk stratification for the individual patient. It is predicted that 
50% of all patients in search of a donor will have donors with permissible HLA-DPB1 mismatches.  
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Avoidance of an unrelated donor with a non-permissive mismatch at HLA-DPB1 might provide a 
practical clinical strategy for lowering the risks of mortality after unrelated-donor hematopoietic-cell 
transplantation. 
 *FHCRC and Dr. Petersdorf’s laboratory manages the IHWG, maintaining a database that 
encompasses clinical information, high-resolution HLA allele typing, and non-HLA genetic 
polymorphisms for over 20,000 unrelated donor transplants performed worldwide since 1996. 
Collectively, the IHWG represents 240 transplant centers, 21 donor and transplant registries, and 37 
laboratories, which work towards understanding barriers posed by genetic variance in 
transplantation. 
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